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Abstract Ferric citrate (FC) has demonstrated efficacy as a
phosphate binder and reduces the requirements for ery-
thropoiesis-stimulating agents (ESAs) and intravenous (IV)
iron in dialysis patients. We developed a net budgetary
impact model to evaluate FC vs. other phosphate binders
from the vantage of a large dialysis provider. We used a
Markov microsimulation model to simulate mutually ref-
erential longitudinal effects between serum phosphate and
phosphate binder dose; categories of these defined health
states. Health states probabilistically determined treatment
attendance and utilization of ESA and IV iron. We derived
model inputs from a retrospective analysis of incident
phosphate binder users from a large dialysis organization
(January 2011–June 2013) and incorporated treatment
effects of FC from a phase III trial. The model was run over
a 1-year time horizon. We considered fixed costs of pro-
viding dialysis; costs of administering ESA and IV iron;
and payment rates for dialysis, ESAs, and IV iron. In the
base-case model, FC had a net budgetary impact (savings)
of ?US$213,223/year per 100 patients treated vs. standard
of care. One-way sensitivity analyses showed a net bud-
getary impact of up to ?US$316,296/year per 100 patients
treated when higher hemoglobin levels observed with FC
translated into a 30% additional ESA dose reduction, and
up to ?US$223,281/year per 100 patients treated when
effects on missed treatment rates were varied. Two-way
sensitivity analyses in which acquisition costs for ESA and
IV iron were varied showed a net budgetary impact of
?US$104,840 to ?US$213,223/year per 100 patients
treated. FC as a first-line phosphate binder would likely
yield substantive savings vs. standard of care under current
reimbursement.
Key Points
Ferric citrate has been shown to be efficacious as a
phosphate binder in end-stage renal disease patients
receiving hemodialysis and also results in reduced
utilization of erythropoiesis-stimulating agents and
intravenous iron, higher hemoglobin levels, and
lower hospitalization rates.
Using a Markov microsimulation model, we show
that under the current reimbursement paradigm, use
of ferric citrate as a first-line phosphate binder is
associated with a base-case cost savings of
approximately US$213,223/year per 100 patients
treated compared with standard of care.
Cost savings arise principally from reductions in
erythropoiesis-stimulating agent and intravenous
iron utilization and in the number of hemodialysis
sessions missed as a result of hospitalizations.
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1 Introduction
Hyperphosphatemia is a nearly ubiquitous consequence of
end-stage renal disease (ESRD) and is associated with
increased risks of mortality and hospitalization [1–6]. The
Kidney Disease Outcomes Quality Initiative guidelines
recommend maintaining serum phosphate levels within the
range of 3.5–5.5 mg/dL. Phosphate homeostasis in patients
receiving dialysis generally requires dietary phosphate
restriction and, frequently, the use of phosphate binders to
prevent systemic absorption [7].
Anemia is another common complication of ESRD
[8, 9]. Patients receiving maintenance dialysis are fre-
quently treated with erythropoiesis-stimulating agents
(ESAs) to stimulate red blood cell production. Iron is
required to support erythropoiesis and patients typically
also receive intravenous (IV) iron [10]. However, the use
of IV iron is associated with hepcidin-mediated iron
sequestration, as well as oxidative stress [11]. Since the
restructuring of dialysis remuneration by the Centers for
Medicare and Medicaid Services Prospective Payment
System, there has been a national shift toward lower
ESA utilization and higher IV iron provision [12, 13].
However, this therapeutic approach, whereby ESA and
iron are used as alternatives, is not well aligned with the
complementary manner in which these agents act
biologically.
The iron-based phosphate binder ferric citrate
(AuryxiaTM; Keryx Biopharmaceuticals, Inc., New York,
NY, USA) has recently completed phase III clinical trials
in the US (NCT01191255, NCT01554982) and Japan
(CTI-111433) and has been approved by the US Food and
Drug Administration. In addition to being safe and effi-
cacious as a phosphate binder, clinical trials have shown
that ferric citrate results in a stable and sustained increase
in serum ferritin levels and transferrin saturation, without
evidence of iron overload. Ferric citrate use also resulted
in reduced utilization of ESA and IV iron, with higher
hemoglobin (Hb) levels and lower hospitalization rates
[14–16].
The objective of the current study was to evaluate the
budgetary impact of ferric citrate as a first-line phosphate
binder from the perspective of a dialysis provider within
the context of the current reimbursement paradigm and
accounting for the effects of ferric citrate on ESA and IV
iron utilization, Hb levels, and the potential for missed
hemodialysis sessions resulting from hospitalizations. To
this end, we constructed a Markov microsimulation model
drawing input data from a retrospective evaluation of
incident users of phosphate binders at a large dialysis
organization (LDO) in the US as well as primary results
from a phase III clinical trial.
2 Methods
2.1 Model Structure Overview
We constructed a Markov microsimulation model using
TreeAge Pro 2013 (TreeAge Software Inc., Williamston,
MA, USA). The model considered 21 health states: 20 based
on permuted categories of serum phosphate (\3.5, 3.5–5.5,
5.6–6.5,[6.5 mg/dL) and phosphate binder dose strength (0,
[0 to\2,C2 to\3,C3 to\4,C4); the 21st state was death,
which was an absorbing state.Wemodeled serum phosphate
and phosphate binder dose strength as continuous tracer
variables and modeled the mutually referential longitudinal
effects between the two as follows (Fig. 1):
1. For each patient, baseline serum phosphate was
assigned probabilisitically.
2. Starting phosphate binder dose strength was then
probabilistically assigned conditional on baseline
phosphate.
3. Interval change in serum phosphate was probabilisti-
cally assigned conditional on preceding serum phos-
phate and phosphate binder dose strength; serum
phosphate in the subsequent interval was defined by
prior value plus interval change.
4. Interval change in phosphate binder dose strength was
probabilistically assigned conditional on preceding
phosphate binder dose strength and serum phosphate;
phosphate binder dose strength in the subsequent
interval was defined by the prior dose strength plus
interval change.
For each interval, probability of death, hemodialysis
treatment attendance, ESA utilization, and IV iron uti-
lization were probabilistically assigned conditional upon
health state. We defined variable revenues and costs by
monetizing these utilization parameters (see below).
We ran the model over a 1-year time horizon and con-
sidered a 1-month cycle length. We used combined first-
and second-order Monte Carlo simulation to fit models.
Each model considered 1000 second-order trials. The
number of random walks (representing patients) was set to
100 to loosely correspond to the number of patients who
might be treated with phosphate binders at a single dialysis
facility. To assess the validity of the model, the modeled
course of serum phosphate, phosphate binder utilization
and mortality were compared with actual values and found
to be comparable.
2.2 Source Data
We derived model input data from a retrospective analysis
of new phosphate binder users from an LDO. Patients
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considered in the source cohort were those who received
in-center hemodialysis at the LDO between January 2011
and June 2013, were enrolled in the LDO’s pharmacy
management program (to ensure visibility to phosphate
binder use), and were incident users of phosphate binders,
defined as receiving an index fill of phosphate binder after
90? days without any phosphate binder supply. We con-
sidered patients forward in time for a maximum of
24 months or until censoring (death, transfer, modality
change, transplant, end of study period). The specific
parameters we estimated for the source cohort were: dis-
tribution of payer mix (Medicare vs. private insurance) as
of index phosphate binder fill; distribution of starting
serum phosphate, estimated from the most recent serum
phosphate measurement preceding the index phosphate
binder fill (within 30 days); frequency distribution of
starting phosphate binder dose strength within each cate-
gory of starting phosphate, where dose strength for indi-
vidual phosphate binders was assigned as described in
Table 1 (which accounts for diminishing incremental effi-
cacy at higher doses) and each simulated patient’s total
phosphate binder strength was determined by summing
strength for each individual agent; distribution of change in
serum phosphate (current interval minus prior interval)
within each category of prior serum phosphate and phos-
phate binder dose strength; frequency distribution of
change in phosphate binder dose strength (current interval
minus prior interval) within each category of prior phos-
phate binder dose strength and concurrent serum
phosphate; probability of death during the cycle based on
categories of concurrent serum phosphate and phosphate
binder dose strength; distributions of ESA dose, IV iron
dose, number of IV iron administrations, and number of
dialysis sessions attended per cycle based on categories of
concurrent serum phosphate and phosphate binder dose
strength. Analytically, ESA dose and IV iron dose were log
transformed and back transformed to the native scale prior
to cost conversion.
We incorporated the effects of ferric citrate from the
results of a phase III clinical trial [14, 15] and applied these
to the ferric citrate group except when patients were
Fig. 1 Schematic of the microsimulation model. At study start, the
patient is probabilistically assigned a starting serum phosphate level
(Phos1) based on the empiric distribution of phosphate levels that
immediately preceded phosphate binder initiation. The phosphate
binder dose strength for cycle 1 (Binder1) is assigned probabilistically
conditional on Phos1. Phos1 and Binder1 determine the patient’s
health state for cycle 1, which probabilistically determines the
number of dialysis treatments received during the period (Treatments
received1), the total dose of ESA and IV iron received during cycle 1
(ESA use1 and IV iron use1) and the probability of death during cycle
1 (Death1). For patients who survive cycle 1, a change in phosphate
between cycle 1 and cycle 2 is probabilistically sampled based on
Phos1 and Binder1; this is added to Phos1 to give serum phosphate in
cycle 2 (Phos2). A change in phosphate binder strength at the start of
cycle 2 is probabilistically sampled conditional on Phos2 and Binder1;
this is added to Binder1 to give binder strength in cycle 2 (Binder2).
Phos2 and Binder2 then define the health state for cycle 2. This
process iterates forward. ESA erythropoiesis-stimulating agent, IV
intravenous
Table 1 Phosphate binder dose strength categories



















a Empirically, very few patients (\2%) started at dose strengths[2.
Starting dose strength was therefore truncated. At later times, simu-
lated patients could transition to higher dose strengths commensurate
with transitions observed in the empiric data
Net Budgetary Impact of Ferric Citrate 161
probabilistically determined to have a phosphate binder
dose strength of zero (i.e., were not on a phosphate binder).
Given the new user design, all patients were on a phosphate
binder at study start, but at later times patients could
transition to no binder use, commensurate with observa-
tions made in the empiric data. Additional information on
model inputs and source data is provided in Online
Resource 1.
2.3 Costing
Costs and revenues considered were: revenue for attended
treatments (payer specific), fixed costs of providing dialy-
sis, cost of ESA, remuneration for ESA (commercial payer
only), cost of IV iron (drug and peripherals/disposables
associated with drug administration), and payment for IV
iron (commercial payer only). Acquisition costs for IV iron
and ESA were based on REDBOOKTM average wholesale
prices (AWP) (accessed 31 March, 2015). Phosphate bin-
der costs were not included in the model as these costs are
not borne by dialysis facilities under current reimburse-
ment policies [17]. Given the short time horizon, we did
not apply discounting.
3 Results
3.1 Model Inputs, Assumptions, Transitions,
and Costs
Retrospective analysis of the LDO database yielded 25,950
patients who met all criteria for inclusion and 321,543
patient-months of observation were assessed. The mean
starting serum phosphate level was 5.4 mg/dL and the
distribution of payer type was 85% Medicare, 15% private
insurance. The distribution of phosphate binder types pre-
scribed at index fill was 47% sevelamer (carbonate or
hydrochloride), 45% calcium acetate, and 7% lanthanum
carbonate. Higher starting serum phosphate level was
associated with higher starting phosphate binder strength:
69% of patients in the highest serum phosphate category
([6.5 mg/dL) started with a phosphate binder dose strength
of 2 vs. 52% of patients in the lowest serum phosphate
category (\3.5 mg/dL). Almost no patients started on a
phosphate binder dose strength of [2; therefore only
strengths of 1, 1.5, and 2 were modeled for initial phos-
phate binder dose strength. Thereafter, modeled phosphate
binder dose strength could exceed 2, commensurate with
patterns observed in the source data.
We estimated the reduction in ESA dose (36%), iron dose
(55%), and number of IV iron administrations (59%) based
on primary study data from a phase III trial [14]. The number
of hospitalizations was reduced by 24%; in the base-case
model, we assumed that this would translate to a 24%
reduction in the number of missed dialysis treatments [15].
Model inputs are summarized in Table 2. Remuneration
for dialysis (considered separately for Medicare and pri-
vately insured patients) and for injected drug administra-
tion (relevant for privately insured patients) was based on
actual values, which are proprietary and cannot be shown.
3.2 Base-Case Analyses
Under base-case assumptions and considered over 1 year,
treatment with ferric citrate vs. standard of care was found to
have anet budgetary impact of?US$213,223/year (p\0.001)
per 100 patients treated with phosphate binder (Table 3).
3.3 Component Costs
Under the base-case scenario, we examined the component
effects of missed treatment reductions, ESA utilization
reduction, and IV iron utilization reduction. Each considered
in isolation, the 24% reduction in missed treatments corre-
sponded to a net budgetary impact of ?US$12,474/year per
100 patients treated; the 36% reduction in ESA utilization
corresponded to a net budgetary impact of ?US$194,652/
year per 100 patients treated; and the 55% reduction in IV
iron utilization corresponded to a net budgetary impact of
?US$5806/year per 100 patients treated (Table 3).
3.4 One-Way Sensitivity Analysis: Effect of Ferric
Citrate on Missed Treatment Rate
The effects of ferric citrate on missed dialysis treatments
per se have not been studied; however, clinical trial data
indicate that ferric citrate use results in a 24% lower hos-
pitalization rate [15]. In base-case models, we assumed that
the number of missed treatments corresponded 1:1 with
hospitalizations; therefore, a 24% reduction in missed
treatments was assumed. However, because ferric citrate
specifically reduced types of hospitalizations that typically
incur longer lengths of stay (cardiovascular, sepsis, gas-
trointestinal), the ratio of missed treatments to hospital-
izations may be greater than 1:1. In a sensitivity analysis,
we assessed the net budgetary impact of ferric citrate
varying the assumed ratio of missed treatments to hospi-
talizations. Varying the ratio of missed sessions to hospi-
talizations to 1.25:1 (30% reduction in missed sessions) or
1.5:1 (36% reduction in missed sessions) resulted in a net
budgetary impact of ferric citrate of ?US$220,366/year per
100 patients treated and ?US$223,281/year per 100
patients treated, respectively (p\ 0.001 for both, Table 4).
Under a maximally conservative assumption whereby fer-
ric citrate use did not translate into any reduction in missed
hemodialysis sessions, the net budgetary impact of ferric
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citrate was ?US$199,220/year per 100 patients treated
(standard error of mean, 14,281; p\ 0.001).
3.5 One-Way Sensitivity Analysis: Effect
of Hemoglobin Differential
In the phase III clinical trial, mean Hb was 0.33 g/dL
higher in ferric citrate-treated patients compared with
control patients. In clinical practice, this magnitude of the
Hb differential may be sufficient to prompt ESA down-
titration in ferric citrate-treated patients, which would
result in incremental reductions in ESA utilization. We
conducted a sensitivity analysis to evaluate the economic
impact of ferric citrate over varied assumptions regarding
the impact of the Hb differential on further ESA reduc-
tions. Specifically, scenarios were considered where the
?0.35 g/dL increase in Hb translated into additional 10,
20, or 30% reductions in ESA. Net budgetary impact was
?US$246,690, ?US$281,758, and ?US$316,296/year per
100 patients treated, respectively (Table 4).
Table 2 Base-case model inputs
Value Source/reference
Model inputs derived from retrospective analysis of LDO patients
Mean (SD) starting serum phosphate, mg/dL 5.4 (1.6) Retrospective analysis of LDO patients
Distribution of primary insurance,%
Medicare 85
Private 15




Starting PB strength based on starting serum phosphate,%
























Model inputs derived from publically available sources
Drug acquistion costs
ESA (Epogen) US$18.24/1000 U REDBOOKTM AWPa
IV iron (iron sucrose) US$8.64/100 mg
Model inputs derived from ferric citrate clinical trials
Effects of ferric citrate:
ESA dose 36% reduction [14, 15]c
IV iron dose 55% reduction
IV iron administrations 59% reduction
Missed dialysis treatmentsb 24% reduction
AWP average wholesale price, ESA erythropoiesis-stimulating agent, Hb hemoglobin, IV intravenous, LDO large dialysis organization, PB
phosphate binder, SD standard deviation
a Accessed 31 March, 2015
b Inferred from hospitalizations, assuming 1:1 ratio of missed dialysis treatments to hospitalizations
c Estimates were modeled from primary clinical trial data
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3.6 Two-Way Sensitivity Analysis Varying ESA
and Iron Costs
Typically, dialysis providers do not pay full wholesale price
for ESAs and IV iron because of rebating. The precise
acquisition cost for these agents varies from provider to pro-
vider and over time within a provider based on negotiated
contracts and data are not publically available. To explore the
impact of ESA and iron costs on the net budgetary impact of
ferric citrate, we performed a two-way sensitivity analysis in
which acquisition costs for ESAs and for IV iron were per-
muted: each from 100 to 50% of listed AWP so as to
encompass all foreseeable circumstances. Across these sce-
narios, the net budgetary impact varied from?US$104,840 to
?US$213,223/year per 100 patients treated (Table 5).Thenet
budgetary impact was more sensitive to differences in ESA
acquisition costs than IV iron acquisition costs.
4 Discussion
The net budgetary impact model presented demonstrates
that if ferric citrate was adopted in wide clinical practice as
a first-line phosphate binder rather than the current
standard of care, cost savings to the dialysis provider would
be approximately US$213,000/year per 100 patients
receiving phosphate binders under current reimbursement
policies. Extrapolation of this value gives estimated cost
savings of US$14.29 per patient per treatment among
patients receiving phosphate binders. Estimated cost sav-
ings arise principally from reductions in ESA utilization
but also from reductions in missed dialysis treatments and
IV iron utilization. The potential range of cost savings
depends in part on a provider’s acquisition cost for ESA,
and whether and how physicians further adjust ESA dose in
response to the ?0.35 g/dL differential in Hb level seen in
ferric citrate-treated patients compared with control
patients. To a lesser extent, potential cost savings depend
on a provider’s acquisition cost for IV iron and to the
extent to which reductions in missed dialysis treatments
mirror the observed reductions in hospitalizations.
Changes to Centers for Medicare and Medicaid Services
reimbursement for hemodialysis in recent years have
affected dialysis facilities’ financial status, with the costs of
providing care exceeding payments received for Medicare
patients. With the implementation of the ESRD Prospective
Payment System in 2011, the dialysis composite rate
payment was expanded to cover the cost of injectable drugs
Table 3 Net budgetary impact of ferric citrate vs. standard of care; base-case model
Net budgetary impact of ferric citrate vs. SOC (US$/year per 100 patients treated)
Mean (SEM) Median [p25; p75] p valuea
Overall ?213,223 (14,111) ?213,018 [203,743; 222,109] \0.001
Component: missed treatment ?12,766 (4276) ?12,474 [9622; 15,748] \0.001
Component: ESA ?194,452 (13,683) ?194,652 [185,618; 203,423] \0.001
Component: IV iron ?5775 (948) ?5806 [5171; 5807] \0.001
ESA erythropoiesis-stimulating agent, IV intravenous, SEM standard error of mean, SOC standard of care
a p value for comparison of mean, ferric citrate vs. SOC
Table 4 Net budgetary impact of ferric citrate vs. standard of care; one-way sensitivity analyses
Net budgetary impact of ferric citrate vs. SOC (US$/year per 100 patients treated)
Mean (SEM) p valuea
Ratio of missed treatments to hospitalizations
1:1 (base case; 24% reduction in missed treatments) ?213,223 (14,111) \0.001
1.25:1 (30% reduction in missed treatments) ?220,366 (14,340) \0.001
1.5:1 (36% reduction in missed treatments) ?223,281 (14,839) \0.001
Implications of Hb differential on ESA utilization, ?0.35 g/dL greater Hb results in:
0% further reduction in ESA (base case) ?213,223 (14,111) \0.001
10% further reduction in ESA ?246,690 (15,871) \0.001
20% further reduction in ESA ?281,758 (19,262) \0.001
30% further reduction in ESA ?316,296 (21,974) \0.001
ESA erythropoiesis-stimulating agent, Hb hemoglobin, SEM standard error of mean, SOC standard of care
a p value for comparison of mean, ferric citrate vs. SOC
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and laboratory tests that were previously separately bill-
able. [12] In November 2013, Centers for Medicare and
Medicaid Services issued its final rule for calendar year
2014, updating payment rates for the ESRD Prospective
Payment System based on an observed[30% drop in drug
utilization (primarily in ESAs) from 2007 to 2012 [17],
which will result in an additional 12% reduction in pay-
ments, implemented over a 3- to 4-year transition period.
A previously published cost-offset model developed
from the perspective of a managed care payer indicated
potential cost savings with ferric citrate between
US$626,000 and US$1,106,000 per year for a very large
individual dialysis facility serving 500 patients [18]. The
current model considered savings from the perspective of a
dialysis provider based on the observed payer mix of
patients who initiated phosphate binders, thus comparison
of the two models is difficult. In addition to the difference
in perspective, several important methodological differ-
ences between the studies should be noted. The previously
published model considered savings as a result of reduc-
tions in ESA and IV iron utilization alone. Moreover, that
model was developed prior to completion of the phase III
US trial of ferric citrate; effects of ferric citrate on ESA and
IV iron use were therefore inferred from changes in serum
ferritin levels and transferrin saturation observed in phase
II trials [19]. Since then, phase III trials have been com-
pleted and the effects of ferric citrate on drug utilization
have been assessed directly, thereby providing real inputs
for the model we describe here.
Several important notes are offered with respect to
interpretation of these data. First, all results are expressed
as differences in the net budget between ferric citrate and
standard of care. These should not be misinterpreted as
absolute profit/loss estimates. Second, cost savings pertain
strictly to patients who are treated with ferric citrate and
not patients who do not receive phosphate binders. Payer
mix among phosphate binder initiators is skewed toward a
higher prevalence of commercial payers because such
patients are, on average, younger than the overall dialysis
population. Therefore, extrapolation of findings to a facility
or provider level should be undertaken cautiously. Third,
the data used to estimate costs were derived based on
contracted rates for a single provider in the US; actual costs
will therefore vary across provider organizations. Fourth,
the effects of ferric citrate on drug utilization and hospi-
talization rates were derived from the findings of a clinical
trial and the effects of the drug in practice are likely to
differ from those observed in randomized controlled trials.
Fifth, model inputs were derived from a retrospective
analysis of incident phosphate binder users who were
enrolled in the LDO’s pharmacy management program. It
cannot be empirically determined whether such patients are
representative of phosphate binder initiators who are not
enrolled in the pharmacy management program because
oral prescription drug data are not available for the latter.
Sixth, the model was developed using data from patients
undergoing hemodialysis. The net budgetary impact of
ferric citrate in patients undergoing hemodiafiltration or
peritoneal dialysis, and in patients with advanced (stage 4
or 5) non-dialysis-requiring chronic kidney disease, who
may also require treatment with phosphate binders, IV iron,
and ESAs, was not estimated. Finally, the model assessed
the net budgetary impact of ferric citrate under the current
reimbursement paradigm where oral medications are
reimbursed separately from dialysis. Therefore, these data
do not pertain to the net budgetary impact of ferric citrate
in the context of an even more comprehensive bundle,
under which dialysis providers assume financial responsi-
bility for the costs of oral drugs used in patients undergoing
dialysis, including phosphate binders.
Strengths of the current model include the robust
source data on which it was based (including phase III
trial results as well as analysis of detailed data from
[25,000 incident patients), the wide array of health states
and inputs considered, and robust sensitivity analyses to
examine the sensitivity of findings to assumptions made
regarding inputs that could not be observed directly in
source data.
Table 5 Net budgetary impact of ferric citrate vs. standard of care in two-way sensitivity analysis in which acquisition costs for ESA and IV iron
are varied
Net budgetary impact of ferric citrate vs.
SOC (US$/year per 100 patients treated)
Acquisition cost for ESAa
50% AWP (US$9.12/1000 U) 75% AWP (US$13.68/1000 U) 100% AWP (US$18.24/1000 U)
Acquisition cost for IV irona
50% AWP (US$4.32/100 mg) ?104,840 ?157,138 ?209,802
75% AWP (US$6.46/100 mg) ?106,946 ?158,680 ?210,447
100% AWP (US$8.64/100 mg) ?108,407 ?160,399 ?213,223
AWP average wholesale price, ESA erythropoiesis-stimulating agent, IV intravenous, SOC standard of care
a Based on REDBOOKTM AWP; accessed 31 March, 2015
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5 Conclusion
The use of ferric citrate as first-line phosphate binder
therapy in patients undergoing hemodialysis was associated
with a favorable US$213,000 budgetary impact per 100
patients receiving phosphate binders per year under the
current reimbursement paradigm.
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